医学
围手术期
循环肿瘤DNA
内科学
肿瘤科
癌症
新辅助治疗
化疗
临床试验
液体活检
基因分型
前瞻性队列研究
实体瘤疗效评价标准
放射科
进行性疾病
乳腺癌
基因型
基因
生物化学
化学
作者
Jiangpeng Wei,Xin Guo,Weiming Duan,Xisheng Yang,Pengfei Yu,Jinqiang Liu,Hushan Zhang,Depei Huang,Zhengqing Yan,Fukun Zhao,Xiaohua Li,Gang Ji
出处
期刊:Research Square - Research Square
日期:2023-03-30
标识
DOI:10.21203/rs.3.rs-2698692/v1
摘要
Abstract Background In gastric cancer, there is a controversial finding regarding the high recurrence rate after neoadjuvant therapy. The use of ctDNA detection for minimal residual disease (MRD) with plasma genotyping has shown higher sensitivity and specificity compared to imaging and serum markers for predicting recurrence. Therefore, we aim to investigate the perioperative dynamic changes in ctDNA in surgical II-III GS patients and assess the efficacy of neoadjuvant chemotherapy. Methods In detail, we will collect blood samples from each patient before neoadjuvant chemotherapy (NAC), after NAC, and one month after surgery. We will also collect tumor tissue before and after NAC. Gene mutations will be detected using a 733-gene NGS panel, and DNA concentrations will be measured. To evaluate the effectiveness of the treatment, we will use RECIST Version 1.1 (RECIST 1.1). Discussion This study aims to assess the correlation between perioperative changes in ctDNA levels and the response to chemotherapy in patients with gastric cancer. It will provide evidence that perioperative ctDNA detection may predict early recurrence, highlighting the potential clinical utility of ctDNA in guiding therapeutic decision-making. Compared to tumor tissue biopsy, ctDNA can non-invasively detect more comprehensive genomic information from a limited amount of plasma. Trial registration: Registered prospectively in the Chinese Clinical Trials Registry with registration number ChiCTR2200060842 on June 12st, 2022.
科研通智能强力驱动
Strongly Powered by AbleSci AI